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Abstract
Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF,
rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3,
rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are
linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in
chronic hepatitis C. Whether these SNPs independently or in combination predict
clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown. We
genotyped SNPs in EGF, PNPLA3, and IL28B from liver tissue from 169 patients
with biopsy-proven HCV cirrhosis. We estimated risk of clinical deterioration,
defined as development of ascites, encephalopathy, variceal hemorrhage, HCC, or
liver-related death using Cox proportional hazards modeling. During a median
follow-up of 6.6 years, 66 of 169 patients experienced clinical deterioration. EGF
non-AA, PNPLA3 non-CC, and IL28B non-CC genotypes were each associated
with increased risk of clinical deterioration in age, sex, and race-adjusted analysis.
Only EGF non-AA genotype was independently associated with increased risk of
clinical deterioration (hazard ratio [HR] 2.87; 95% confidence interval [CI] 1.31–
6.25) after additionally adjusting for bilirubin, albumin, and platelets. Compared to
subjects who had 0–1 unfavorable genotypes, the HR for clinical deterioration was
1.79 (95%CI 0.96–3.35) for 2 unfavorable genotypes and 4.03 (95%CI 2.13–7.62)
for unfavorable genotypes for all three loci (Ptrend,0.0001). In conclusion, among
HCV cirrhotics, EGF non-AA genotype is independently associated with increased
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risk for clinical deterioration. Specific PNPLA3 and IL28B genotypes also appear to
be associated with clinical deterioration. These SNPs have potential to identify
patients with HCV-related cirrhosis who require more intensive monitoring for
decompensation or future therapies preventing disease progression.
Introduction
Chronic hepatitis C (CHC) is the most common cause of liver-related death and
liver transplantation in the United States [1]. The rate of progression of hepatitis
C virus (HCV) infection is variable, likely due to a combination of host genetic
and environmental factors. At least 20% of patients with CHC develop cirrhosis
over a twenty-year period [2]. Once cirrhosis is established, patients are at risk for
hepatocellular carcinoma (HCC) and decompensation, characterized by ascites,
variceal hemorrhage, or hepatic encephalopathy (HE), and survival decreases
from a median of 12 years to 2 years [3].
Attempts have been made to develop risk scores to predict the risk of disease
progression for individual patients. Such scores have incorporated both clinical
variables and genetic data [4]. The possibility of tailoring clinical management to
genetic data is exciting, but the discovery of ever-increasing numbers of single
nucleotide polymorphisms (SNPs) associated with liver disease mandates careful
selection of polymorphisms that have independent predictive value for relevant
outcomes. One of the genetic variations for which there is compelling evidence is
the rs12979860 SNP near the interleukin-28B (IL28B) locus. The CC IL28B
genotype is associated with spontaneous clearance of HCV and predicts interferon
and ribavirin treatment response [5, 6]. However, data regarding an independent
association between IL28B genotype and disease course are conflicting [7–9]. The
epidermal growth factor (EGF) gene polymorphism rs4444903 has been associated
with EGF levels [10], HCC [10, 11] and fibrosis [12]. Last, while the patatin-like
phospholipase domain-containing protein 3 (PNPLA3) SNP rs738409 has mainly
been studied in nonalcoholic fatty liver disease (NAFLD) [13], studies in patients
with CHC have shown an association with steatosis, fibrosis [14, 15], and HCC
[15, 16], although data are conflicting [17].
These data suggest that these SNPs may be useful for the prediction of the
natural history of CHC. However, no study has evaluated the influence of IL28B,
EGF, and PNPLA3 genotypes on the natural history of HCV-related cirrhosis or
examined these SNPs in the same population. We therefore sought to evaluate the
association between these SNPs and clinical deterioration in a cohort of patients
with HCV-related cirrhosis.
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Materials and Methods
Cohort assembly
The patient cohort was identified from pathology reports at Massachusetts
General Hospital. A natural language search for biopsies performed between 1990
and 2007 was previously performed for the keywords: HCV, HBV, NAFLD,
NASH, and hepatitis. Pathology reports were reviewed to identify patients whose
biopsies were consistent with HCV-related cirrhosis. Inclusion criteria were age
$18 years at time of biopsy, positive HCV antibody or HCV RNA, and presence
of cirrhosis (Ishak stage 5 or 6/6 or Metavir stage 4/4). Exclusion criteria included
co-infection with human immunodeficiency virus or hepatitis B virus (HBV),
liver transplantation, ascites, variceal hemorrhage, HE, or HCC prior to or within
one month of the biopsy, and lack of follow-up data following the biopsy. The
electronic medical records of patients identified by the pathology database search
as having biopsies consistent with HCV-related cirrhosis were manually reviewed
by two independent reviewers. The keyword search of the pathology database
yielded 370 patients whose reports were consistent with a diagnosis of HCV-
related cirrhosis. After review of the medical record, 220 patients were eligible.
Formalin-fixed, paraffin-embedded (FFPE) blocks were not available for 38
patients, and genotyping could not be performed on 13 patients. Thus, the final
cohort included 169 patients (Fig. 1). Nine patients overlapped with the cohort in
which we previously identified the association between EGF genotype and HCC
[10]. This study was approved by the Partners Human Research Committee. The
Committee waived the need for written, informed consent for this retrospective
study. All data was analyzed anonymously.
Ascertainment of Outcomes
The follow-up period for each patient was defined as the date of the index biopsy
until the occurrence of the first episode of clinical deterioration, death, loss to
follow-up, or December 31, 2012, whichever came first. Clinical deterioration was
defined as the development of ascites, HE, variceal hemorrhage, HCC, or liver-
related death. Outcomes were identified by manual chart review performed by two
independent reviewers. The primary outcome was the time to the first episode of
clinical deterioration after the index biopsy.
Other covariates
We collected the following baseline variables from the electronic medical record:
age, gender, race, medical history, body mass index, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), total bilirubin, albumin, platelet count,
creatinine, international normalized ratio [18] (INR), prothrombin time, HCV
genotype and HCV RNA, alcohol use, and smoking history. For all baseline
laboratory values, we used the value determined at the time of the index biopsy. If
no value was available at that time, we used the value collected closest to the
biopsy within the year prior to the biopsy. Heavy alcohol use was defined as
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documentation of alcohol abuse or dependence, a history of substance abuse
counseling, or consumption .14 drinks per week by males or .7 drinks per week
by females. Diabetes was defined as a history of diabetes mellitus in the medical
record or the use of diabetic medications. The number of subjects with incomplete
data was 48 for HCV RNA; 39 for creatinine; 22 for HCV genotype; 16 for either
prothrombin time or INR; 13 for smoking status; 13 for ALT, AST, albumin, total
bilirubin; 9 for platelets; and 8 for alcohol use.
Fig. 1. Flow chart for identification of the cohort. The following keywords were used in the pathology
database search: HCV, HBV, NAFLD, NASH, and hepatitis. HCV: hepatitis C virus; HBV: hepatitis B virus;
HIV: human immunodeficiency virus; HCC: hepatocellular carcinoma; FFPE: formalin-fixed, paraffin-
embedded;
doi:10.1371/journal.pone.0114747.g001
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Genotyping
DNA was extracted from FFPE liver tissue (Five 10 mm sections from each
patient) using the QiaAMP FFPE Tissue Kit (Qiagen Inc, Valencia, CA).
Genotyping was performed on 5 ng of DNA using the 7900HT Fast Real-Time
PCR System with commercial TaqMan SNP Genotyping Assays for IL28B
rs12979860, EGF rs4444903, and PNPLA3 rs738409 (Life Technologies, Grand
Island, NY) according to the manufacturer’s instructions. Genotypes were
assigned using Sequence Detection System (SDS 2.4) software with manual review
by two independent investigators, blinded to subject phenotype.
Statistical analysis
We calculated the person-years of follow-up for each individual from the date of
the biopsy to the development of the first episode of clinical deterioration, date of
death, or end of follow-up, whichever came first. Kaplan-Meier method was used
to analyze the time to clinical deterioration. The log rank test was used for
comparison between genotypes. The crude and adjusted hazard ratios (HRs) and
95% confidence intervals (CIs) for the effect of the SNPs on the rate of clinical
deterioration were estimated with Cox proportional hazards regression models.
The proportional hazard assumption was checked via the statistical significance of
the interaction between log (follow-up time) and genotype. For our primary
analysis, we examined each SNP in an age, sex, and race-adjusted model. In a
secondary analysis, we also examined the association of each SNP in a
multivariable model additionally adjusting for established predictors of clinical
deterioration including baseline albumin, platelets, and total bilirubin [3, 19].
Lastly, we included all 3 SNPs in a combined genotype model in which we
compared subjects who had an unfavorable genotype for all 3 SNPs to subjects
who had two, one or zero unfavorable genotypes.
We performed several sensitivity analyses. First, we performed an analysis
excluding HCC and HCC-related death as a first outcome. For this analysis, we
calculated the person-years of follow-up for each individual from the date of
biopsy to the development of the first episode of ascites, variceal hemorrhage, HE,
date of death, or end of follow-up, whichever came first. Second, we performed an
analysis incorporating sustained virologic response (SVR) at any point prior to
the censor date into the model given the known association between IL28B
genotype and SVR. Third, we performed an analysis excluding the one subject
who had an outcome within 6 months of the index biopsy. Finally, we performed
an analysis excluding subjects who were Child-Pugh Class B or missing a Child-
Pugh score because of missing laboratory data. A 2-tailed P-value ,0.05 was
considered statistically significant. SAS (Cary, NC) version 9.3 was used for
statistical analyses.
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Results
Among the 169 patients with biopsy-proven HCV-related cirrhosis, the baseline
demographic and clinical data according to EGF, IL28B, and PNPLA3 genotypes
are shown in Table 1. The mean age of the cohort was 50¡9 years. The cohort
was predominantly Caucasian (84%), male (74%) and had Child-Pugh Class A
(93%) or Class B (7%) cirrhosis. After a median follow-up of 6.6 years (IQR: 4.7–
9.2 years), 66 (39%) patients developed at least one episode of clinical
deterioration. Outcomes included death related to portopulmonary hypertension,
n51; ascites, n518; variceal hemorrhage, n513; HE n57; HCC, n518; ascites
and HE, n57; variceal hemorrhage and HE, n51; and ascites and variceal
hemorrhage, n51.
To evaluate the association of genotype independent of other clinical factors, we
used multivariable models adjusted for age, sex, and race (Table 2; Fig. 2).
Compared with AA genotype, EGF non-AA genotype was associated with an age,
sex, and race-adjusted HR of 3.20 (95% CI 1.57–6.52; p50.001) for clinical
deterioration. Compared with CC genotype, IL28B non-CC genotype was
associated with an age, sex, and race-adjusted HR of 1.78 (95%CI 1.03–3.06;
p50.04) for clinical deterioration. Compared with CC genotype, PNPLA3 non-
CC genotype was associated with an age, sex, race-adjusted HR of 1.79 (95%CI
1.10–2.90; p50.02) for clinical deterioration.
In multivariable models with age, race, sex and established predictors of disease
progression including albumin, platelets, and total bilirubin, EGF non-AA
genotype remained an independent predictor of increased risk of clinical
deterioration, multivariable-adjusted HR52.87 (95% CI 1.31–6.25; p50.008)
(Table 2). In contrast, there was no longer a significant association between IL28B
genotype (multivariable-adjusted HR 1.38; 95%CI 0.71–2.68; p50.34 for non-CC
compared with CC) and PNPLA3 genotype (multivariable HR 1.45; 95%CI 0.85–
2.47, p50.17 for non-CC compared with CC) and clinical deterioration.
When all three SNPs were analyzed together, the presence of 3 unfavorable
genotypes (EGF non-AA, IL28B non-CC, and PNPLA3 non-CC, HR 4.03; 95%CI
2.13–7.62) and 2 unfavorable genotypes (HR 1.79; 95%CI 0.96–3.35) were
associated with a significantly increased risk of clinical deterioration compared to
the presence of one or zero unfavorable genotypes (Plinear trend,0.0001) (Table 3).
When we excluded a single subject who developed an outcome within 6 months
of the index biopsy, the HRs for the association of the SNPs with risk of clinical
deterioration were not materially altered. We performed a sensitivity analysis
limiting the outcome to the time to development of ascites, variceal hemorrhage,
or HE. EGF non-AA genotype remained a significant predictor of increased risk of
clinical deterioration (age, sex, race-adjusted HR52.93; 95%CI 1.30–6.60;
p50.01). The association between PNPLA3 genotype and clinical deterioration
also persisted (age, sex, race-adjusted HR51.93; 95%CI 1.10–3.37; p50.02 for
non-CC compared to CC). However, the association between IL28B genotype and
clinical deterioration was no longer significant (age, sex, race-adjusted HR51.52;
95%CI 0.83–2.79; p50.18 for non-CC compared to CC). We also conducted
Host Genetics and Deterioration in HCV
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Table 1. Baseline Characteristics of all patients and stratified by genotype.
Entire cohort EGF AA EGF AG/GG IL28B CC IL28B CT/TT PNPLA3 CC
PNPLA3 CG/
GG
Number 169 45 82/42 66 75/28 102 51/16
Age, years 50.1(9.3) 51.6(7.6) 49.6(9.8) 51.2(9.8) 49.4(8.6) 50.4(8.8) 49.6(10.1)
Male, % 74 69 76 68 78 72 78
Race
White, % 84 89 82 91 80 85 82
Black, % 5 4 6 2 8 8 2
Hispanic,% 7 2 8 3 9 2 13
Other, % 4 4 4 4 4 5 3
Ever smoker, % 63 53 67 56 68 65 61
History of heavy
alcohol use, %
51 53 51 42 57 52 51
Diabetes Mellitus, % 13 9 15 6 17 13 13
HCV RNA .500,000,
IU/mL, %
47 53 44 53 43 45 49
Genotype 1, % 63 64 62 55 68 58 70
AST, U/L 115.3(73.8) 110.8(88.1) 117.0(67.8) 103.4(64.6) 122.5(78.2) 106.3(59.1) 128.7(90.4)
ALT, U/L 139.4(113.0) 134.1(111.0) 131.5(114.1) 142.4(118.6) 137.6(109.9) 129.1(98.5) 154.8(130.7)
Albumin, g/dL 3.8(0.5) 3.8(0.4) 3.8(0.6) 3.9(0.5) 3.7(0.5) 3.8(0.5) 3.7(0.5)
Creatinine, mg/dL 0.9(0.5) 1.0(0.8) 0.9(0.2) 0.9(0.2) 0.9(0.5) 1.0(0.6) 0.9(0.2)
Total Bilirubin, mg/dL 0.9(1.1) 0.7(0.4) 0.9(1.2) 0.66(0.3) 1.0(1.3) 0.9(1.3) 0.8(0.5)
Platelets 61000/mm3 152.4(59.4) 170.0(49.5) 145.8(61.7) 161.3(59.8) 146.6(58.8) 156.1(60.8) 146.5(57.1)
Entire




A, % 82 91 78 82 82 81 82
B, % 7 2 8 2 10 7 6
Unknown, % 12 7 14 17 9 12 12
Continuous Variables are presented as mean (SD).
EGF: Epidermal Growth Factor; IL28B: interleukin-28B; PNPLA3: patatin-like phospholipase domain-containing protein 3; HCV: hepatitis C virus; AST:
aspartate aminotransferase; ALT: alanine aminotransferase.
doi:10.1371/journal.pone.0114747.t001
Table 2. Cox proportional Hazards Model for Clinical Deterioration.
Genotype Cases/Person-Years
Age, sex, race- Adjusted
Hazard Ratio (95%CI) P value
Multivariable Adjusted Hazard
Ratio* (95% CI) P value
EGF AA 9/390 1.00 1.00
EGF non-AA 57/812 3.20 (1.57–6.52) 0.001 2.87 (1.31–6.25) 0.008
IL28B CC 19/506 1.00 1.00
IL28B non-CC 47/697 1.78 (1.03–3.06) 0.04 1.38 (0.71–2.68) 0.34
PNPLA3 CC 32/752 1.00 1.00
PNPLA3 non-CC 34/451 1.79 (1.10–2.90) 0.02 1.45 (0.85–2.47) 0.17
*Adjusted for age, sex, race, and baseline total bilirubin, albumin, and platelets.
EGF: Epidermal Growth Factor; IL28B: interleukin-28B; PNPLA3: patatin-like phospholipase domain-containing protein 3; CI: confidence interval.
doi:10.1371/journal.pone.0114747.t002
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analyses restricted to those with Child-Pugh Class A cirrhosis, and found that EGF
non-AA genotype was associated with the risk of clinical deterioration in Child-
Pugh Class A subjects (age, sex, race-adjusted HR53.30; 95%CI 1.46–7.35;
p50.004). The significant association between PNPLA3 genotype and risk of
clinical deterioration also persisted (age, sex, race-adjusted HR52.04; 95%CI
1.16–3.60; p50.01 for non-CC compared with CC). The association between
IL28B genotype and risk of clinical deterioration did not remain statistically
significant (age, sex, race-adjusted HR51.81; 95%CI 0.95–3.48; p50.07 for non-
CC compared with CC).
One hundred twenty-six patients (75%) received some course of antiviral
therapy with either interferon alfa alone or interferon alfa and ribavirin following
the index biopsy. Among these, forty patients (32%) achieved a SVR to antiviral
therapy. Among these forty patients, only 3 patients developed clinical
deterioration. One patient had an episode of variceal hemorrhage and two
patients developed HCC. When we incorporated achievement of SVR into the age,
sex, and race-adjusted model, EGF non-AA genotype remained a significant
predictor of increased risk of clinical deterioration (HR52.74; 95%CI 1.32–5.67;
p50.007). There were no longer significant associations between IL28B genotype
(age, sex, race-adjusted HR 1.61; 95%CI 0.93–2.79; p50.09 for non-CC compared
with CC) and PNPLA3 genotype (age, sex, and race-adjusted HR 1.56; 95%CI
0.96–2.56; p50.07 for non-CC compared with CC) and clinical deterioration. The
addition of SVR to the age, sex, and race-adjusted model with all 3 loci did not
materially alter the results.
Fig. 2. Kaplan-Meier analysis of clinical deterioration by genotype. A. Kaplan-Meier analysis of the time to
first episode of ascites, variceal hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, or liver-
related death stratified by EGF genotype. B. Kaplan-Meier analysis of time to first episode of ascites, variceal
hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, or liver-related death stratified by IL28B
genotype. C. Kaplan-Meier analysis of time to first episode of ascites, variceal hemorrhage, hepatic
encephalopathy, hepatocellular carcinoma, or liver-related death stratified by PNPLA3 genotype. EGF:
Epidermal Growth Factor; IL28B: Interleukin-28B; PNPLA3: patatin-like phospholipase domain-containing
protein 3.
doi:10.1371/journal.pone.0114747.g002
Table 3. Combined genotype model.
Genotypes Cases/Person-Years Age, sex, race-Adjusted Hazard Ratio (95%CI) P value*
0/1 unfavorable genotypes+ 18/569 1.00
2 unfavorable genotypes 23/424 1.79 (0.96–3.35) 0.07
3 unfavorable genotypes 25/209 4.03 (2.13–7.62) ,0.0001
*Plinear trend,0.0001.
+unfavorable genotypes include EGF non-AA, IL28B non-CC, and PNPLA3 non-CC.
EGF: Epidermal Growth Factor; IL28B: interleukin-28B; PNPLA3: patatin-like phospholipase domain-containing protein 3; CI: confidence interval.
doi:10.1371/journal.pone.0114747.t003
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Discussion
We found significant associations between EGF, IL28B, and PNPLA3 genotypes
and the risk of clinical deterioration in patients with HCV-related cirrhosis. The
risk associated with EGF genotype persisted, even after adjustment for known
clinical predictors of progression, including albumin, bilirubin, and platelets.
These results suggest that genetic variation at the EGF locus is independently
associated with clinical deterioration in patients with CHC and provides
prognostic information beyond known clinical predictors. In contrast, genetic
variations at IL28B and PNPLA3 loci were associated with prognosis in age, sex,
and race-adjusted models, but the association was no longer statistically
significant after adjustment for albumin, bilirubin, and platelets. This may reflect
either a weaker association of these polymorphisms with clinical deterioration
compared with the EGF polymorphism or the possibility that the effect of the
IL28B and PNPLA3 polymorphisms on clinical deterioration may be mediated by
these clinical factors. Thus, controlling for these variables may mask a true
biological relation. Our combined analysis shows that the risk of clinical
deterioration significantly increases with the presence of each unfavorable
genotype and suggests that all three SNPs in concert could be useful in predicting
disease progression.
Our findings are consistent with prior data regarding the EGF locus and clinical
outcome in liver disease. We previously found that the EGF AG and GG genotypes
are associated with a two to four-fold increased risk for HCC [10]. Moreover, EGF
expression, as assessed in a gene expression signature in non-tumoral liver tissue,
is associated with poor survival in HCC patients after resection and with
progression to advanced cirrhosis, HCC development and poor survival in HCV-
related early-stage cirrhosis [20, 21]. Our findings extend the results of these
studies by identifying a role for the EGF locus independently or in concert with
two additional SNPs in not only the development of HCC but also the progression
of HCV-related cirrhosis. Consistent with these results is a cross-sectional study
showing that the G allele of EGF rs4444903 is associated with higher degrees of
liver fibrosis in younger subjects with CHC [12].
Our results are consistent with the functional nature of EGF rs4444903. We
have previously reported increased stability of EGF 61*G allele transcripts
compared to EGF 61*A allele transcripts in human hepatoma cell lines and
primary human hepatocytes as well as increased levels of serum and liver EGF in
subjects with cirrhosis who have the EGF GG versus AA genotype [10].
Additionally, the EGF receptor (EGFR) [22] and its HRas signaling pathway have
been identified as host factors for HCV cellular entry [23]. HCV infection also
induces EGFR signaling in cell culture models [24] and increases EGFR expression
in HCV-infected patients [23]. Taken together with our study, these findings
support a key role for EGF in the mediation of CHC-related liver damage.
Our finding of an association between increased risk of clinical deterioration
and the IL28B non-CC genotype in age, sex, and race-adjusted analysis is
supported by evidence that carriage of the T allele is associated with fibrosis
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severity, cirrhosis and HCC in CHC [7, 9]. In contrast to our results, however, one
group showed that the CC genotype was associated with increased risk for adverse
clinical outcomes [8]. This group also found no association between IL28B
genotype and fibrosis progression. The difference in our findings may be related
to the fact that their cohort consisted of patients who were prior non-responders
to interferon and ribavirin and had advanced fibrosis or cirrhosis. Of note, the
association between IL28B genotype and clinical deterioration was not significant
in our analysis when restricted to Child Pugh Class A subjects or after excluding
HCC from the definition of the primary outcome. This may reflect limited power
in this smaller cohort and potentially a more limited role for the IL28B genotype
in hepatic decompensation compared with development of HCC. The association
between IL28B genotype and clinical deterioration was also no longer significant
after adjustment for SVR. This likely reflects the fact that the impact of IL28B on
clinical deterioration is mediated through response to therapy or potentially
limited power to detect the association in the larger model.
Our results showing an association between PNPLA3 non-CC genotype and
risk of clinical deterioration in age, sex, and race-adjusted analysis is supported by
a study showing an association between the PNPLA3 C.G polymorphism and
fibrosis progression in CHC [14] and a meta-analysis showing an association
between this polymorphism and hepatocarcinogenesis in subjects of European
descent [16].
Our study has several limitations. First, we excluded sixteen subjects from the
multivariable model adjusting for known predictors of disease progression due to
missing laboratory variables. This may have limited our power to detect the
association between the PNPLA3 and IL28B polymorphisms and clinical
deterioration in analyses adjusted for established laboratory predictors of
outcome. Second, we did not have information on disease duration prior to the
biopsy. However, no patients had evidence of decompensated liver disease prior to
the biopsy and our results were consistent even among those with Child-Pugh
Class A disease. Third, because the index biopsies were performed between 1990
and 2007, we did not have reliable information quantifying the amount of
steatosis on each biopsy, and thus could not incorporate this into our
multivariable model. While steatosis has been shown to predict fibrosis
progression prior to the development of cirrhosis, it has not been shown to
predict decompensation once cirrhosis has occurred. Fourth, our population was
predominantly Caucasian males, limiting the external generalizability of our
findings. However, recent meta-analyses revealed that although allele frequencies
of the EGF polymorphism vary according to race, the association between EGF
genotype and HCC risk appears independent of race [25, 26]. Nonetheless, further
studies are required to validate our findings in more diverse cohorts. Last, we only
examined clinical deterioration among individuals with hepatitis C-related
cirrhosis. It is unknown if our findings would be similar among patients with
other etiologies of cirrhosis. However, a recent study reported an association
between carriage of the EGF G allele and cirrhosis in 62 subjects with chronic HBV
infection [27].
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In conclusion, our findings support a role for EGF and possibly IL28B and
PNPLA3 genotyping in identifying persons with CHC at high risk for disease
progression. In light of our group’s finding that pharmacological inhibition of
EGFR with erlotinib prevented progression of cirrhosis and regressed fibrosis in
animal models of progressive cirrhosis [28], EGFR inhibition may be a promising
therapeutic approach for reduction of fibrogenesis and prevention of HCC in high
risk patients. Taken together with the known association of genetic variation in
the EGF gene with EGF levels, our data support the potential for EGF genotyping
to identify patients who may be candidates for strategies to modulate EGF.
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